Dora Y Ho, MD
Infectious Disease · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ho’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A80640 · Current
Licensed to practise in California · since 2002 · expires 2028-01-31 · Washington University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$67,787
Medicare paid this office $67,787 for 187 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $21,428 | $106 |
| Long return visit (40+ min) | 59 | $20,936 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,346 | $155 |
| Long return visit (40+ min) | 19 | $4,668 | $126 |
| New patient visit (60+ min) | 20 | $4,015 | $201 |
See all 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $21,428 | $106 |
| Long return visit (40+ min) | 59 | $20,936 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $8,346 | $155 |
| Long return visit (40+ min) | 19 | $4,668 | $126 |
| New patient visit (60+ min) | 20 | $4,015 | $201 |
| New patient visit (60+ min) | 14 | $2,270 | $162 |
| Return visit (30+ min) | 16 | $2,104 | $124 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 22 | $539 | $15 |
Who their Medicare patients are
187 Original Medicare patients in 2024. Average age 70 · Women 39% · Also on Medicaid 34% · Health risk score 4.19. Sicker patients than 9 in 10 peers; the typical infectious disease clinician is at 3.
Conditions among them: High blood pressure 75% · Chronic kidney disease 53% · Diabetes 47% · Coronary heart disease 43% · Heart failure 37% · Atrial fibrillation 34% · Depression 29% · COPD 28% · Cancer 27% · Dementia 17% · Stroke 17%.
The office billed $308,521, Medicare allowed $86,750 and paid $67,787; for 561 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 187 | 561 | 70 | 4.19 | $308,521 | $67,787 |
| 2023 | 197 | 632 | 69 | 3.96 | $308,245 | $73,896 |
| 2022 | 186 | 612 | 68 | 3.82 | $304,925 | $65,977 |
| 2021 | 199 | 697 | 68 | 3.71 | $350,795 | $77,359 |
| 2020 | 216 | 655 | 68 | 3.54 | $275,444 | $69,985 |
| 2019 | 240 | 755 | 67 | 3.77 | $258,166 | $81,774 |
| 2018 | 197 | 677 | 66 | 3.73 | $226,452 | $72,479 |
| 2017 | 180 | 652 | 66 | 3.83 | $225,678 | $68,121 |
| 2016 | 173 | 688 | 65 | 3.65 | $244,890 | $69,510 |
| 2015 | 140 | 539 | 67 | 3.87 | $185,558 | $55,240 |
| 2014 | 175 | 754 | 65 | 3.58 | $256,274 | $75,593 |
| 2013 | 145 | 585 | 65 | 3.35 | $202,955 | $59,352 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 91 | $33,554 | $108 |
| Long return visit (40+ min) | 69 | $17,555 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $13,434 | $160 |
| New patient visit (60+ min) | 24 | $3,711 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $2,627 | $71 |
| Return visit (30+ min) | 18 | $1,807 | $86 |
2022: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 77 | $27,821 | $94 |
| Long return visit (40+ min) | 53 | $12,943 | $131 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $11,373 | $181 |
| New patient visit (60+ min) | 33 | $5,368 | $163 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,005 | $65 |
| Return visit (30+ min) | 22 | $2,621 | $85 |
2021: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 83 | $35,092 | $94 |
| Long return visit (40+ min) | 70 | $15,657 | $136 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $12,879 | $181 |
| New patient visit (60+ min) | 39 | $6,526 | $167 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $3,452 | $65 |
| Return visit (30+ min) | 26 | $2,759 | $95 |
2020: 8 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $32,036 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 78 | $15,514 | $189 |
| Long return visit (40+ min) | 65 | $8,174 | $98 |
| New patient visit (60+ min) | 23 | $3,323 | $144 |
| Return visit (30+ min) | 34 | $2,876 | $67 |
| New patient visit (45+ min) | 22 | $2,630 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,758 | $68 |
| Telephone medical discussion with physician, 21-30 minutes | 16 | $1,476 | $74 |
2019: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 110 | $36,860 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 104 | $20,604 | $182 |
| Long return visit (40+ min) | 86 | $14,019 | $97 |
| New patient visit (60+ min) | 33 | $5,026 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,508 | $66 |
| Return visit (30+ min) | 17 | $1,364 | $72 |
2018: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 85 | $33,048 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 91 | $17,783 | $181 |
| Long return visit (40+ min) | 73 | $11,152 | $94 |
| New patient visit (60+ min) | 20 | $3,010 | $151 |
| Long return visit (40+ min) | 23 | $2,594 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,026 | $65 |
2017: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 93 | $32,536 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 71 | $14,404 | $180 |
| Long return visit (40+ min) | 75 | $13,600 | $97 |
| New patient visit (60+ min) | 30 | $4,231 | $141 |
| Return visit (30+ min) | 16 | $1,278 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,166 | $65 |
2016: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 70 | $37,129 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $11,897 | $180 |
| Long return visit (40+ min) | 71 | $10,977 | $90 |
| New patient visit (60+ min) | 31 | $4,381 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,929 | $64 |
| Return visit (30+ min) | 16 | $1,295 | $68 |
2015: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $25,849 | $92 |
| Long return visit (40+ min) | 49 | $12,649 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 53 | $10,120 | $181 |
| New patient visit (60+ min) | 24 | $3,365 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,227 | $65 |
| Return visit (30+ min) | 14 | $982 | $58 |
2014: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 88 | $39,463 | $92 |
| Long return visit (40+ min) | 63 | $14,429 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $12,411 | $180 |
| New patient visit (60+ min) | 29 | $3,975 | $137 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $3,074 | $64 |
| Return visit (30+ min) | 15 | $1,119 | $70 |
2013: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $30,071 | $90 |
| Long return visit (40+ min) | 57 | $12,682 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 61 | $11,559 | $175 |
| New patient visit (60+ min) | 21 | $2,872 | $137 |
Medicaid work
$3,241 in 2024
Medicaid paid $3,241 for 75 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 75 | $3,241 |
| 2024 | 75 | 1 | 12 | $3,241 |
| 2023 | 12 | 1 | 12 | $637 |
| 2020 | 69 | 1 | 16 | $2,471 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 12 | $637 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 69 | $2,471 |
Drugs they prescribed that Part D paid
$363,234
Pharmacies billed $363,234 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 297) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
258 generic and 39 brand-name prescriptions · $363,234 in drug cost · 190 antibiotic prescriptions to 35 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nuzyra | 11 | $160,519 | $14,593 |
| Cresemba | 25 | $155,513 | $6,221 |
| Aztreonam | 54 | $34,768 | $644 |
| Ertapenem | 13 | $2,873 | $221 |
| Piperacillin-Tazobactam | 12 | $1,171 | $98 |
See all 10 drugs
| Nuzyra | 11 | $160,519 | $14,593 |
| Cresemba | 25 | $155,513 | $6,221 |
| Aztreonam | 54 | $34,768 | $644 |
| Ertapenem | 13 | $2,873 | $221 |
| Piperacillin-Tazobactam | 12 | $1,171 | $98 |
| Famciclovir | 13 | $792 | $61 |
| Fluconazole | 16 | $386 | $24 |
| Acyclovir | 18 | $261 | $15 |
| Isoniazid | 17 | $163 | $10 |
| Sulfamethoxazole-Trimethoprim | 23 | $56 | $2 |
Year by year
| 2024 | 297 | 49 | 0% (0) | 13% | $363,234 |
| 2023 | 243 | 42 | 0% (0) | 14% | $364,424 |
| 2022 | 191 | 45 | 0% (0) | 18% | $220,638 |
| 2021 | 217 | 49 | 0% (0) | 11% | $176,623 |
| 2020 | 241 | 56 | 0% (0) | 12% | $115,446 |
| 2019 | 191 | 49 | 0% (0) | 12% | $170,708 |
| 2018 | 193 | 42 | 0% (0) | 21% | $229,801 |
| 2017 | 194 | 42 | 0% (0) | 40% | $320,572 |
| 2016 | 153 | 38 | 0% (0) | 33% | $125,405 |
| 2015 | 230 | 35 | 0% (0) | None | $182,113 |
| 2014 | 184 | 36 | 0% (0) | 41% | $176,631 |
| 2013 | 126 | 30 | 0% (0) | 24% | $122,517 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Nuzyra | 12 | $198,995 | $16,583 |
| Cresemba | 18 | $126,308 | $7,017 |
| Aztreonam | 29 | $24,533 | $846 |
| Fluconazole | 30 | $5,269 | $176 |
| Ceftazidime | 28 | $2,668 | $95 |
| Cefadroxil | 11 | $817 | $74 |
| Acyclovir | 15 | $399 | $27 |
| Famciclovir | 13 | $367 | $28 |
| Sulfamethoxazole-Trimethoprim | 21 | $158 | $8 |
2022: 7 drugs
| Cresemba | 21 | $127,767 | $6,084 |
| Fluconazole | 20 | $2,400 | $120 |
| Cefadroxil | 12 | $921 | $77 |
| Famciclovir | 12 | $625 | $52 |
| Acyclovir | 19 | $369 | $19 |
| Isoniazid | 11 | $160 | $15 |
| Sulfamethoxazole-Trimethoprim | 16 | $48 | $3 |
2021: 8 drugs
| Cresemba | 17 | $94,139 | $5,538 |
| Valganciclovir | 12 | $2,106 | $176 |
| Rifampin | 13 | $850 | $65 |
| Sulfamethoxazole-Trimethoprim | 15 | $688 | $46 |
| Famciclovir | 11 | $607 | $55 |
| Isoniazid | 29 | $242 | $8 |
| Doxycycline Hyclate | 11 | $197 | $18 |
| Acyclovir | 14 | $144 | $10 |
2020: 7 drugs
| Cresemba | 11 | $58,404 | $5,309 |
| Rifampin | 23 | $1,376 | $60 |
| Vancomycin | 11 | $1,007 | $92 |
| Cephalexin | 11 | $452 | $41 |
| Isoniazid | 50 | $371 | $7 |
| Doxycycline Hyclate | 11 | $274 | $25 |
| Acyclovir | 14 | $213 | $15 |
2019: 5 drugs
| Noxafil | 13 | $113,886 | $8,760 |
| Ethambutol | 11 | $1,219 | $111 |
| Rifampin | 13 | $1,095 | $84 |
| Acyclovir | 18 | $257 | $14 |
| Isoniazid | 25 | $187 | $7 |
2018: 6 drugs
| Noxafil | 19 | $141,182 | $7,431 |
| Rifampin | 11 | $436 | $40 |
| Ciprofloxacin | 16 | $288 | $18 |
| Acyclovir | 16 | $190 | $12 |
| Sulfamethoxazole-Trimethoprim | 22 | $166 | $8 |
| Isoniazid | 11 | $101 | $9 |
2017: 7 drugs
| Noxafil | 35 | $216,889 | $6,197 |
| Cresemba | 12 | $51,482 | $4,290 |
| Cancidas | 11 | $25,996 | $2,363 |
| Invanz | 14 | $11,099 | $793 |
| Fluconazole | 17 | $3,109 | $183 |
| Rifampin | 14 | $925 | $66 |
| Isoniazid | 27 | $197 | $7 |
2016: 1 drug
| Cresemba | 11 | $45,722 | $4,157 |
2015: 5 drugs
| Voriconazole | 23 | $41,942 | $1,824 |
| Sodium Chloride | 41 | $941 | $23 |
| Sulfamethoxazole-Trimethoprim | 14 | $160 | $11 |
| Isoniazid | 20 | $134 | $7 |
| Cephalexin | 12 | $103 | $9 |
2014: 7 drugs
| Voriconazole | 24 | $52,524 | $2,188 |
| Cancidas | 17 | $48,449 | $2,850 |
| Noxafil | 12 | $42,200 | $3,517 |
| Fluconazole | 13 | $1,975 | $152 |
| Sodium Chloride | 22 | $448 | $20 |
| Sulfamethoxazole-Trimethoprim | 14 | $164 | $12 |
| Cephalexin | 11 | $69 | $6 |
2013: 4 drugs
| Voriconazole | 19 | $39,277 | $2,067 |
| Penicillin Gk-Iso-Osm Dextrose | 11 | $5,454 | $496 |
| Fluconazole | 14 | $1,437 | $103 |
| Rifampin | 12 | $869 | $72 |
Money from drug and device companies
$18 in 2024
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Prevymis | $18 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Education · 2024-06-22 | Prevymis | $18 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1619032224
- Licence
- CA A80640California A80640: Current · expires 2028-01-31
- Trained
- Washington University School of Medicine, 2001
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X)
- Mailing address
- 300 Pasteur Dr Rm S-169, Stanford, CA, 94305
- NPI first listed
- 2006-12-26
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.